Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Yeah we'll see how it goes. PUMA jumped back in front of him now so.....But ultimately I agree with you, til we get one of the big catalysts/milestones we'll be stuck down here in this range. Even when a stock starts to run people bail very quickly now, so it will have to be good to want to make people go long.
What do you think about ETRF MAGA? Seems they might be also trying to accumulate shares around this level. I think they've popped up several times with some bigger BIDS.
Exactly. Lot of cleanup for Charles to do over the past 2 yrs dealing with the old ENZC and what Harry left him to deal with. As far as what Charles & Co brought to the table, it's now in the hands of one of the largest CDMO's in the world less than a year after merging so, not bad if you ask me. I've said this before and I will say it again, there was no possible way for ENZC to live up the sp explosion ?? that happened, an impossible task. The only way for them now to do that is to be ultimately successful with either ITV-1 or Clone 3.
Thx Foxi and excellent technical analysis as always!
I would think the biggest catalyst that could come anytime now is the last toxicology report for ITV-1, which basically is the same as getting drug approval in a handful of African countries, while also opening the door in Europe for trials. Tough time of year, but investors also need to hear/see something to get excited again about ENZC, and bring back some investment here. Lots of folks on the sidelines taking a wait and see approach at the moment, gone are the days where people would just jump in on the slightest of news/rumor.
Yep, no problem.....What is your outlook as far as the charts? I know it's not a favorable one, as we have broken below the 50 dma once again. Looks like a low vol pullback as of late, probably just trending downwards towards the support area around .03?
Here is a good read/article on why Charles went this route if anyone is interested.....
https://ipwatchdog.com/2020/11/22/time-board-pct-train-benefits-filing-us-patent-applications-via-pct-first/id=127518/#
Very hard to say and it's complicated MAGA on how these patent applications work and how they gain approval. But it will go into the national phase in 30 months from when it was submitted, which was 2/2021, so that is around Aug 2023.
Yes, the Anti-HIV PCT patent application was determined to be both novel & inventive, and it's a guarantee basically that it will be approved in the US and all countries they apply for patents. As far as the Coronavirus one, that one was deemed inventive but not novel, but Charles says this is normal as they didn't review all 39 claims, and it is a regular occurrence that claims may be initially objected to but later allowed after argument and submission of relevant evidence to the Patent Office.
Yeah they were never disclosed from the start, which was to be expected. This is the nature with bios at this stage however, could be a lull for very long periods until something significant happens, which we all know the catalysts by now.
They were actively looking into proposals last November for their animal mabs, and now they have identified a partner for those mabs, but obviously that is still being withheld for the moment, but could hear something anytime.
I'm with ya. I would have thought we would have a couple by the end of the year, but that's why expecting or timing any catalysts with any certainty is always a tough game.
But in the end everything rides with Clone 3. It's the exact reason why Fauci went after what we had already patented with Clone 3 back in 1989, and it wasn't so they could cure AIDS with it, they were definitely going to shelve it. Bioclonetics never could get the necessary funding, and we can all guess or assume why, even though Fauci admitted to Clone 3 having commercial value.
Now we have the recombinant form of the parent monoclonal antibody, and it's like 30x more powerful than the parent antibody. This is how we probably landed Samsung Biologics, sharing our in vitro testing. Just have to get over the last hurdle or 2, and we can finally get the ball rolling with this.
Also, PUMA is using a fairly large spread tactic between the BID/ASK, trying to shy people away from hitting the ASK, so they can fill shares lower on the BID. Retail gets in the way every now and then but they have been pretty successful.
I agree. They are definitely accumulating very slowly and calculating. And can do it under the radar while there is no catalyst or much retail buying interest to drive up the price. And yes this time of year is always tough, lots of people selling for tax purposes and just not much going on in general. I would expect things to hopefully pickup beginning of Jan, especially in the news/catalyst department.
I hear ya MAGA, I think the biggest one right now could be the final toxicity test. That's like getting drug approval for ITV-1 in those African countries. Also, IND and funding/partner source to start animal trials for Clone 3 would be massive.
Just curious, how is ENZC doing since the announced LOI in Sep 2020?
Oh for sure MAGA, I'm definitely with you on the over deliver/under promise way to go about things at this point. That's why when Charles said IPF would be available in November, with only like 2 weeks left in the month of Nov and one of them was Thanksgiving, I thought it was already a done deal pretty much and I'm sure so did he.
Ultimately have to get past the IPF and audited financials sort of debacle or whatever you want to call it. And I agree it will at least do some good to restore some confidence, although I think we may get a pump from the audited fins temporarily, I don't think it's a catalyst to hold a major increase in sp.
So Valentin was giving a total a 5 million series E stock for 2 million bucks, gotcha.
Yeah I think this sort of financing is meant to get them to the milestones necessary, probably animal trials, to land a large equity partner for clinical trials. They may or already have said equity partners, just need to show milestone completion.
Ok thx Foxi. I was just looking at the most recent quarterly, and didn't see it in there but may have just missed it.
All good pts MAGA and I agree with you to a certain extent. It's obvious that they are relying upon the people they hire to get things done for them, and in the case of IPF it's NPI. Easy to judge from the outside looking in, but the truth is we really have no clue and we are just speculating/guessing what the problem is at this point. I would also expect communication soon if the product is not available, as the optics of the situation look horrible.
Not trying to justify anything or give them any sort of pass, but the truth is the we are going to be relying on the co/people we hire for just about everything we do, as we we are not experts in any of the fields as far as drug trials or supplements or what have you.
We hired Tom Nelson of Ten Associates, and I think most people thought that was a huge mistake/disaster from the start. Took over a year to finally get rid of him.
Yeah they have done that 3x now, all went to Valentin Dimitrov for CASH. Doesn't say how much was received but the shares are restricted.
It's definitely trending that way MAGA, but still doesn't have the necessary vol as of right night to do much either way. That could change if we get a 10-15 million vol day with 80% sells however. Hard to say/know because there is no way to tell where the true support lies here.
I hear ya. Better PUMA though then STXG, who never buys and only sells I would think. That was also a brutal month from Sep til Oct with them in charge. Bottom line is without major interest from retail, we are kinda at the mercy here until something big drops imo.
Good morning MAGA......Do you think PUMA has been accumulating lately? Hard to imagine they are short covering.
Yeah I get that Timing, and I normally don't ever respond, as I have been here for a long time, more than most. So I'm comfortable with ENZC and where they are at and what they are doing. I get that share price is everything to most people, and it that regard a lot of folks bought in that historic run from Jan to early Feb, and even afterwards, and are down substantially. So ENZC will not be able to live up to that standard if we are just looking at sp at the high until now, at least not for the foreseeable future.
Let's do this. How about you show me other r&d biotech companies that have only been around for 2 years, and show me all the achievements they have made in that amount of time? And keep in mind this was right in the middle of the pandemic, where everything was delayed.
I mean what you are expecting from ENZC is not conceivable or has been achieved from even the biggest and greatest biotechs of all-time. When ENZC fails to start trials for ITV-1 or Clone 3, or fails during any of the clinical trials if they get to that pt, then you can talk. And even then they have their IP and AI Platform that would still probably give them value. This co is in it's infancy, and will take many years to make any sort of judgement like you are doing imo.
For sure. It's so hard to put an accurate mc on a pre-revenue drug development biotech. Hence why you will get wild fluctuations, especially so early on in the process. I mean look at us when we reached a mc briefly that was 2.5 billion, just a few short months after the merger. But over time, milestones/achievements will start to play a role in significantly increasing the mc. Right now I would say we are in sort of a lull stage, things being produced and going on in the background, but most are just in wait and see mode.
But what I do know from looking at other OTC tickers, and their values being in the 50-100 million range, and that includes them being massively diluting on a reg basis, very little revs, and just overall pump and dumps in my opinion, that ENZC should always maintain a certain level of mc that should not be that much below where we stand now.
Yeah Dec can always be tricky with tax loss harvesting, but last Dec I think there was a lot of that going on, with the huge amount of losses that were incurred in 2021. In 2020, we had ran to over a dime, and were way above the 50 dma at the time, so I just believe it was taken down to that level by the mm and ultimately held and bounced from there, just like all the stocks were doing at the time. Right now the vol is extremely low, so going to need more vol to move this thing one way or the other.
I agree. Before Charles took over and the eventual merger of ENZC & Bioclonetics, ENZC was a total disaster of a co, albeit with a drug like ITV-1 in their possession. But obviously Harry was not the man to get the job done and basically the co was dead in the water, especially financially, hence the reason the stock was also trip zeros.
I think many are underestimating what Charles has done over the last 2 years, the moves he has made to not only protect the co but also the shareholders. Keeping overhead expenses very light while still not diluting basically nothing. Not sure any other CEO of a drug development co at this stage could or would be willing to do that.
Missteps, delays, and lost partners have all happened in the last 2 years, but nothing is ever perfect and all part of the process in trying to go from a extremely small unknown bio to competing and winning against the big boys. Not an easy task by any means.
I posted this in the Discord, and I think it's kind of flown under the radar.
Just a friendly reminder from the Nov 8, 2021 PR which states this at the end......"The Company is actively exploring proposals for collaborations and partnerships with U.S. and foreign veterinary companies for their monoclonal antibodies for veterinary use."
Couple that with Aug 22 co news update stating they have already identified a veterinary mab partner, and I think it's safe to say they have probably been working together now for quite sometime. Just a matter of when it will be announced.
I say this because there is always usually a nugget or 2 in these big co updates we get every so often, where Charles is basically telling you without telling you, because of NDA's or simply wanting to stay quiet waiting for the right time. Just like Abveris was mentioned in the Aug 22 update without actually being named. To me this is huge news but hasn't really been absorbed yet because it hasn't been officially pr'd....
The 2 big names in veterinary Mabs would be Merck Animal Health & Zoetis. We announce something like this, it will go a long way in confirming our ability to land partners of this magnitude.
Never looked into that angle but you could be right MAGA. Maybe there was pressure to cancel the deal, or maybe the deal was prematurely announced, either way ENZC recovered with getting Samsung Biologics, which imo is a very comparable CDMO to Lonza.
Well, as of a few days ago in the latest co PR, Charles states this......"the Company has a strong working relationship with Samsung Biologics"......So either Charles is lying or that would definitely be news to him if they had walked away. Also, I know that Samsung Biologics would not want them being advertised together if the relationship ended, and you would see them removed from their website as a partner.
The Lonza deal we may never know the exact reason, but Savov played a big role in sabotaging and losing a long-term partner right before Lonza, or the deal just fell through for other reasons. Things happen but we were able to secure Samsung Biologics just a few short months afterwards, and have been working with them for 14 months now.
I mean he has expressed a lot of confidence in the Aug 22 co news update, saying he will be able to raise the necessary funds for all the verticals. Hasn't diluted or even thought about it yet so, either they have partner(s) right now, or definitely lined up when the time comes. Either way I would love to see an equity partnership announced. I mean there is no way ENZC is really going to bring a drug through clinical trials by themselves, although Charles has said he would if he had to, so they are obviously looking to partner up. Readily admitted they have no experience in doing so or the desire.
So just like with everything, we are dependent on our partners or who we hire for everything. IR, audits, ITV-1, IPF, Clone 3...... Those decisions can also make or break you as a co, hopefully our choices are the right ones, but obviously hiring mistakes have already been made.
No, I agree MAGA, it was definitely coordinated/planned, to perfection I might add.....lol
Exactly! ITV-1, Clone 3, AI Platform are the big 3. BP does not care about the things many on here are complaining/bitching about, it's all about does the drug work and how much money can they make from said drug.
There is no question that the US & Fauci admitted that Clone 3 had commerical value and tried to infringe/steal our patent at the time. Hence the reason why Charles is operating and will continue to operate in the manner he does, with the utmost importance on our IP and not letting things be known publicly until it's time.
MAGA, good follow-up and you like me have been here a long time, well before the merger, and we have watched L2 literally 6.5 hrs a day, 5 days a week!....lol
1) Once the LOI came out with intent to merge back in September 2020, there were a lot of naysayers/doubt that it would ever happen. Pretty much anything Charles said would happen, getting pink current, merging etc, happened and pretty much on time. I know for a fact that Charles & Co were not ready for the onslaught of investors/fans/notoriety. I think they were completely caught off guard with this, and soon after Dr Chandra took over as the face of the co, with social media and all the Hicks interviews. I think his last Twitter post beforehand was like in March 2020, so he himself was not really on Twitter much at all before this merger. Well, social media we know can be a brutal place, places like Twitter, IHUB, and Stocktwits are not for the feint of heart by any means. Did he pump in his own way with hashtags and such! Absolutely! But everything he said was true to the best of his knowledge at the time. He's problem was he started taking the attacks personally, and naturally you would want to defend yourself and company. But missed timelines/deadlines, along with a rapidly declining sp, compounded the problem for him. Let's face it, at the end of the day it's all about the mighty dollar for a overwhelming amount of people, which is natural and why you are in the market.
As far as the audit, I guess the chose the route of updates via the quarterlies and PR's. They must have had thousands of emails, hence the reason they made the decision to hire Tom Nelson. Another thing Charles I think realized early on, and the stock took a major hit, was that Emerging Growth Conference. What happened leading up to that and the destruction of sp the next few days, was breathtaking. It was extremely hyped/pumped for no reason, as we all knew there wasn't going to be anything shares we didn't already know, but the sp as soon as Charles started to talk was tanking almost immediately. The interviewer was terrible, and the aftermath was not pretty. So I just think that Charles understands things to the pt that if they did something before and it turned out badly, they would not repeat the same mistake twice. So I'm with you on the second launch of IPF, I didn't think we would hear or see anything except to find out one day you could start ordering it and a subsequent pr.
The mm is tough to deal with but all part of the OTC and the game. When there is liquidity and major retail interest, you are less affected. Yes, a majority of retail has been turned off with OTC, delays, macro environment, etc. So right now we are in a weather the storm mode and trying to find where are ultimate bottom is. I do believe Charles & Dr C that all milestones will eventually be achieved. Not saying they will all be successful, but I do believe they will achieve to get done what they set out to do.
With Samsung, these companies received IND approval with 30 days of application, and generally speaking you don't hear any updates regarding the IND until it comes out. I mean I guess we could hear that we applied when the time comes, but I'm not expecting it.
Yep, no problem......
1) Samsung Biologics......I realize that Samsung Biologics claims to go from gene to IND in 9 months, but from the companies I've seen so far that has not been the case. Now, these companies started with Samsung in 2018 or so, so maybe the technology and speed today can get in done much faster, but from what I see it's around 2 yrs before approval.......https://www.prnewswire.com/news-releases/samsung-biologics-national-oncoventure-and-eutilex-obtain-ind-approval-from-fda-301215739.html........https://www.pressreader.com/korea-republic/the-korea-times/20200424/281509343331449
2) Audited Financials...... Obviously this has not gone the way ENZC or any of us wanted from the beginning and the hiring of M&B. Remember M&B said we did a reverse merger not a business combination, so we needed the books of Bioclonetics to also be audited for those 2 yrs, which it turned out we actually did do a business combination. So that was obviously a huge issue 6 months into the auditing process. They even hired Steven Heumann from Eisner & Amper to assist with this. Unless Charles is lying in the quarterly reports, he always maintained there was no issues or questions from M&B, and he provided them with all the necessary documentation. Now what was the straw that broke the camels back this summer that caused them to fire M&B, is anyones guess. But you simply don't go through this length to get an audit done, hire independent counsel, to not ultimately get the audit completed. When will this happen? Who knows but I would expect either this month or next at the latest.
3) IPF IMMUNE......Now this is the one the optically looks the worse, as we initially came out with a PR back in Nov 21 talking about introducing IPF in early 2022. It was definitely hyped/pumped leading up to the supposed release in March. Everything seemed to be a go as Onelavi took orders, product was supposedly here as we saw evidence of, and then the FDA label issue. Coincidence? Maybe, but we know how things sometimes go with the powers that be. Turns out supply was also an issue so it has given them time to hopefully get stocked up and prepared for the release soon.
Final note......ENZC is a drug development co, and the business combination that took place between Charles & Harry back in 2020, also coincided with greatest pump in OTC history, which caused ENZC to go from trip zeros to almost a dollar in less than 6 months. Where we were at in that particular time, there was literally no place for ENZC to go but way down. They could have been absolutely perfect with everything they did and this would have still took a massive hit, these are just the facts imo. To say it's a longshot to get a drug to market is a understatement to say the least, and many people will bash and hate on ENZC no doubt, and a overwhelming majority of the time they will be correct, just like almost all OTC stocks/companies will never go anywhere. But nobody can say for certain either way, as we are not even in pre-clinical trials yet for there 2 major drugs, ITV-1 & Clone 3. As we sit at just above .04 cents, I can't think of many other OTC companies that have the kind of verticals we have in the biotech space, that have only diluted once in the amount of 32 million shares, and I believe those were restricted. Delays and mistakes, sure. But the fact that they have not reached into investors pockets the last 2 yrs should speak volumes imo, as the overhead costs are extremely low and exactly what you would want from a co like ENZC with basically 4-6 employees. It will all eventually boil down to the science, and then we can all judge whether or not ENZC was a success or failure. But it's also the reason you can still buy it for pennies, with a lot risk right now but also could be very rewarding.
Of all those listed, PUMA is one which can make you pull your hair out more often than not. A lot of times you will see PUMA on the high bid and rarely, if ever, on the ask. Then, there are times where you will see PUMA boxed in (on the high bid and the high ask) with a wide enough spread to “scalp” the in between as well as scare investors into selling to them on the bid.
What PUMA will be looking to accomplish is one of two things: either accumulating ahead of an anticipated public event, or a short covering before a possible move to the upside. Either way, this battle can last weeks and makes seeing them atop the bid/ask of a ticker one you will only want to enter into if it’s understood you could be there for awhile.
Looks like exactly what has been taking place on Level 2 here.
Talked with IR guy yesterday who I have spoken with before a few times. Not a whole lot to report really, still making products. Murray has stepped down, guess he's been wanting to for awhile, health reasons and supposedly he's a numbers guy but never knew how to run a company, so we'll see if this new ceo does any better. Still testing at Syncrude, but nothing by the way of any purchase orders that I see. Supply chain is better but still having trouble getting some parts. MC is like 1.6 million now, but just like the rest of the OTC, liquidity has dried up big time, so until that comes back a bit I don't see much happening in general.
I have read what you are saying, but I'm just waiting/wanting the product to be available for purchase here. Improving the website can be worked on or fixed in the future. I'm sure all they are concerned about is getting the product launched at this point.
There are 2 court cases, the one you are referring to is the Nevada Court case where Savov is suing the transfer agent of ENZC to release the 72 million shares to him. He's looked ridiculously foolish in this case, and has lost everything so far pertaining to it. The judge will undoubtedly stay the case, as she referred to the ongoing case in Delaware, meaning until that dispute is resolved she will not rule on this case. All he is doing is trying to circumvent and leapfrog the Delaware case.